Europe's Sleep Crisis Costs Over €300 Billion as Disorders Surge Ahead of Diabetes

A new study has examined the impact of sleep disorders across 47 European countries. The research highlights their growing economic and health burdens, with costs rising faster than those of diabetes or heart disease. Five key conditions were analysed: obstructive sleep apnea, insomnia, narcolepsy, restless legs syndrome, and REM sleep behavior disorder.

The findings reveal that insomnia affects around 10 percent of adults over 20. Obstructive sleep apnea is even more common, with an estimated 18 percent prevalence in those over 30. Restless legs syndrome impacts about 3 percent of adults over 20, while narcolepsy and REM sleep behavior disorder are far rarer, at 0.03 percent and 0.009 percent respectively.

Economically, the burden is substantial. In high-income European nations, sleep disorders now cost €326.4 billion annually. Over the past five years, direct costs in countries like Germany, France, and the UK have jumped by 15–20 percent, exceeding €50 billion per year. Indirect costs, such as lost productivity, surged by 25 percent, reaching €100–150 billion. This increase outpaces the economic rise of other major health issues, including diabetes and cardiovascular diseases.

Despite these figures, researchers note that the full scale of sleep disorders remains understudied. Their effects extend beyond finances, influencing brain function, physical health, and broader societal well-being.

The study underscores the need for greater attention to sleep disorders in Europe. Their economic impact has grown sharply, now exceeding €300 billion yearly in high-income nations. With millions affected by conditions like insomnia and sleep apnea, further research and policy action may be required to address the rising costs and health consequences.